Daniel S. Chen
Ten Chen Hospital(TW)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Angiogenesis and VEGF in Cancer, CAR-T cell therapy research, Bladder and Urothelial Cancer Treatments
Most-Cited Works
- → Oncology Meets Immunology: The Cancer-Immunity Cycle(2013)6,760 cited
- → TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells(2018)5,347 cited
- → Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients(2014)5,215 cited
- → Elements of cancer immunity and the cancer–immune set point(2017)5,167 cited
- → Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial(2016)4,726 cited
- → Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial(2016)2,785 cited
- → VEGF in Signaling and Disease: Beyond Discovery and Development(2019)2,619 cited
- → MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer(2014)2,413 cited
- → Top 10 Challenges in Cancer Immunotherapy(2020)2,223 cited
- → Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma(2018)1,227 cited